Top Story

ST2 levels predicted acute GVHD, mortality after double-unit cord blood transplantation

December 19, 2014

High levels of the biomarker suppressor of tumorigenicity 2 at 28 days post-cord blood transplantation independently predicted acute graft-versus-host disease, according to study results.

High levels of tumorigenicity 2 (ST2) also predicted transplant-related mortality, results showed.

In the Journals

Anticoagulant, antiplatelet medications carry rare dermatologic surgery hemorrhage risks

December 19, 2014
Dermatologists and dermatologic surgeons should be aware of the bleeding risks of anticoagulant and antiplatelet drugs used for cardiovascular diseases, according to…
In the Journals

Nonenhanced neck CT may detect diffuse thyroid disease

December 19, 2014
Nonenhanced CT images are effective for differentiating diffuse thyroid disease from normal thyroid, according to recent findings published in the International Journal
Richard Pazdur, MD FDA approvals

FDA approves Lynparza, companion diagnostic for advanced ovarian cancer

December 19, 2014
The FDA today approved olaparib for heavily pretreated women with advanced ovarian cancer associated with BRCA mutations.The approval also included a companion…
Meeting News Coverage

Study results show no clear link between calcium channel blockers, breast cancer

December 19, 2014
CHICAGO — Analysis of a potential link between use of calcium channel blockers and risk for breast cancer yielded conflicting results in two separate cohorts…
More News Headlines »
CME
Hot melanoma

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
IBIS-I: Tamoxifen provides long-term protection for women at high risk for breast cancer

IBIS-I: Tamoxifen provides long-term protection for women at high risk for breast cancer

December 12, 2014
SAN ANTONIO — Erin W. Hofstatter, MD, director of the Breast Cancer Genetics and Prevention Program at Yale…
More »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »